2024-09-28 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global pharmaceutical company that develops, manufactures, and markets a range of prescription drugs, primarily in the areas of immunology, oncology, virology, neurology, and eye care.

**1. Performance Comparison:**

* **Cumulative Return:**  ABBV has outperformed the S&P 500 (VOO) with a cumulative return of 150.12% versus 134.22% for VOO. This represents a difference of 15.9% or a relative outperformance of 57.45% based on historical data.

**2. Recent Price Action:**

* **Closing Price:** $191.9
* **5-Day Moving Average:** $192.99
* **20-Day Moving Average:** $194.54
* **60-Day Moving Average:** $186.93
* **Current Trend:**  The price is slightly below its 5-day and 20-day moving averages, indicating a slight short-term downward trend. It is above the 60-day moving average, suggesting long-term upward momentum.

**3. Technical Indicators:**

* **RSI:** 46.52 - Currently in the neutral range, suggesting neither overbought nor oversold conditions.
* **PPO:** -0.41 -  Negative value suggests potential bearish sentiment, though it's relatively close to zero.
* **Delta_Previous_Relative_Divergence:** -10.19 - This indicates a short-term downward trend in the relative strength of the stock compared to its historical performance.
* **Expected Return:** 5.32% - This represents a potential 5-year expected return on investment based on current data.

**4. Recent Earnings and Outlook:**

| Date       | EPS       | Expected EPS |
|------------|-----------|--------------|
| 2024-07-25 | 2.65      | 2.57          |
| 2024-04-26 | 2.31      | 2.26          |
| 2024-02-02 | 2.79      | 2.76          |
| 2023-10-27 | 2.95      | 2.86          |
| 2023-07-27 | 2.91      | 2.79          |

The most recent earnings (2024-07-25) exceeded expectations by 0.08, indicating positive performance. AbbVie has consistently surpassed earnings estimates in recent quarters, demonstrating its profitability and potential for future growth.

**5. News and Recent Issues:**

* **Recent Market Outlook for ABBV:**
    * **FINBOLD**: Reports positive news regarding the company's upcoming Humira biosimilar launch, expecting continued growth in the oncology segment and potential for further acquisitions.
    * **Analysts:** Many analysts maintain a "Buy" or "Strong Buy" rating on ABBV, highlighting its strong fundamentals, consistent earnings, and growth prospects.
* **Performance Highlights:**
    * AbbVie's strong earnings performance has been driven by its successful Humira franchise and its ongoing investments in R&D for new drugs, particularly in oncology.
    * The company has shown resilience in the face of market volatility and continues to invest in key growth areas.

**6. Summary:**

ABBV has consistently outperformed the S&P 500 and shows positive growth momentum. Recent earnings have surpassed expectations, indicating solid financial performance. Although the stock is currently experiencing a slight downward trend in the short term, its long-term outlook appears favorable with a positive 5-year expected return. AbbVie's continued investment in research and development, expansion into new markets, and potential for further acquisitions solidify its position as a strong contender in the pharmaceutical industry.

**7. Key Points for Investors:**

* ABBV has a history of strong performance and has outpaced the S&P 500 in recent years.
* The company boasts a robust financial position with consistent earnings and a strong pipeline of new drugs.
* Although short-term market fluctuations may occur, ABBV offers long-term growth potential and a solid investment opportunity. 
